Teva Pharmaceutical Industries (TEVA) Net Cash Flow (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Net Cash Flow came in at -$81.0 million in Q2 2026, down 117.27% YoY from $469.0 million in Q2 2025, and down 140.1% on a QoQ basis from $202.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Net Cash Flow (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Net Cash Flow data on file, last reported at -$81.0 million in Q2 2026.
- Quarterly Net Cash Flow fell 117.27% year-over-year to -$81.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 1434.78% YoY) and the FY2025 annual result came in at $235.0 million, down 5.24% from the prior year.
- Net Cash Flow slipped to -$81.0 million in Q2 2026, from $202.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.4 billion in Q4 2025 to a low of -$1.6 billion in Q1 2025.
- A 5-year average of $99.2 million and a median of $108.5 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow surged 1686.11% — and 2025, when it plunged 1158.02%.
- Tracing TEVA's Net Cash Flow over 5 years: stood at $430.0 million in 2022, then soared by 111.4% to $909.0 million in 2023, then tumbled by 88.67% to $103.0 million in 2024, then jumped by 1223.3% to $1.4 billion in 2025, then plunged by 105.94% to -$81.0 million in 2026.
- The last three Net Cash Flow figures came in at -$81.0 million (Q2 2026), $202.0 million (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 159.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -81.00 Mn |
| Jun 30, 2026 | -81.00 Mn |
| Mar 31, 2026 | 202.00 Mn |
| Mar 31, 2026 | 202.00 Mn |
| Dec 31, 2025 | 1.36 Bn |
| Dec 31, 2025 | 1.36 Bn |
| Sep 30, 2025 | 51.00 Mn |
| Sep 30, 2025 | 51.00 Mn |
| Jun 30, 2025 | 469.00 Mn |
| Jun 30, 2025 | 469.00 Mn |
| Mar 31, 2025 | -1.65 Bn |
| Mar 31, 2025 | -1.65 Bn |
| Dec 31, 2024 | 103.00 Mn |
| Dec 31, 2024 | 103.00 Mn |
| Sep 30, 2024 | 961.00 Mn |
| Sep 30, 2024 | 961.00 Mn |
| Jun 30, 2024 | -685.00 Mn |
| Jun 30, 2024 | -685.00 Mn |
| Mar 31, 2024 | -131.00 Mn |
| Mar 31, 2024 | -131.00 Mn |